Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates

Dianthus Therapeutics Reports Q2 2025 Earnings: Revenue Misses, EPS in Line with Estimates

DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) reported its second-quarter 2025 financial results, with revenue falling short of analyst expectations while the net loss per share aligned closely with estimates. The clinical-stage biotech company posted revenue of $193,000, significantly below the consensus estimate of $881,616. Earnings per share (EPS) came in at -$0.88, matching the anticipated -$0.89.

Key Financial Takeaways

• Revenue: Reported $193K vs. estimated $881.6K (a substantial miss).
• EPS: Reported -$0.88 vs. estimated -$0.89 (in line).
• Cash Position: $309.1 million in cash and equivalents, extending the company’s runway into the second half of 2027.
• R&D Expenses: Increased to $26.3 million, up from $18.1 million in Q2 2024, driven by clinical trial and manufacturing costs.
• Net Loss: $31.6 million, compared to $17.6 million in the prior-year quarter.

Market Reaction

The stock has shown muted movement in after-hours trading, with no significant price action following the earnings release. Over the past month, shares have declined by approximately 3.3%, while the two-week performance reflects a 7.7% drop. The lack of a sharp reaction suggests investors were largely prepared for the earnings miss, given the company’s clinical-stage status and focus on long-term pipeline development rather than near-term revenue.

Pipeline and Business Updates

Dianthus provided updates on its lead candidate, claseprubart (DNTH103), a monoclonal antibody targeting autoimmune diseases:

• Phase 2 MaGic Trial (gMG): Top-line results expected in September 2025.
• Phase 3 CAPTIVATE Trial (CIDP): Interim responder analysis anticipated in the second half of 2026.
• Phase 2 MoMeNtum Trial (MMN): Top-line data expected in late 2026.

Management emphasized the potential of claseprubart to address unmet needs in neuromuscular disorders, particularly with its convenient subcutaneous administration. CEO Marino Garcia highlighted the multibillion-dollar market opportunity in generalized myasthenia gravis (gMG), where only about 10% of patients currently use FcRn or complement therapies.

Outlook vs. Analyst Estimates

While Dianthus did not provide explicit financial guidance, analysts project:

• Q3 2025 Revenue Estimate: $918.4K
• Q3 2025 EPS Estimate: -$0.93
• Full-Year 2025 Revenue Estimate: $3.83 million
• Full-Year 2025 EPS Estimate: -$3.40

The company’s cash reserves provide ample funding for ongoing trials, reducing near-term financing risks.

Conclusion

Dianthus Therapeutics remains focused on advancing its clinical programs, with key data readouts expected over the next 12-18 months. The revenue miss in Q2 is unlikely to deter long-term investors, given the company’s cash position and upcoming catalysts.

For more detailed earnings estimates and historical performance, visit Dianthus Therapeutics Earnings & Estimates.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.